BRPI0815330A2 - métodos e composições para tratar cânceres - Google Patents

métodos e composições para tratar cânceres

Info

Publication number
BRPI0815330A2
BRPI0815330A2 BRPI0815330A BRPI0815330A BRPI0815330A2 BR PI0815330 A2 BRPI0815330 A2 BR PI0815330A2 BR PI0815330 A BRPI0815330 A BR PI0815330A BR PI0815330 A BRPI0815330 A BR PI0815330A BR PI0815330 A2 BRPI0815330 A2 BR PI0815330A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
treating cancers
cancers
treating
Prior art date
Application number
BRPI0815330A
Other languages
English (en)
Inventor
Dierks Christine
Warmuth Markus
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0815330A2 publication Critical patent/BRPI0815330A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0815330A 2007-08-16 2008-08-13 métodos e composições para tratar cânceres BRPI0815330A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95629507P 2007-08-16 2007-08-16
PCT/US2008/073049 WO2009026075A1 (en) 2007-08-16 2008-08-13 Methods and compositions for treating cancers

Publications (1)

Publication Number Publication Date
BRPI0815330A2 true BRPI0815330A2 (pt) 2017-05-09

Family

ID=40210407

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815330A BRPI0815330A2 (pt) 2007-08-16 2008-08-13 métodos e composições para tratar cânceres

Country Status (16)

Country Link
US (3) US20100216828A1 (pt)
EP (1) EP2187967B1 (pt)
JP (1) JP2010536775A (pt)
KR (1) KR20100056525A (pt)
CN (1) CN101820915A (pt)
AU (1) AU2008289255B2 (pt)
BR (1) BRPI0815330A2 (pt)
CA (1) CA2699988A1 (pt)
DK (1) DK2187967T3 (pt)
ES (1) ES2422285T3 (pt)
HR (1) HRP20130642T1 (pt)
MX (1) MX2010001813A (pt)
PL (1) PL2187967T3 (pt)
RU (1) RU2010109452A (pt)
SI (1) SI2187967T1 (pt)
WO (1) WO2009026075A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009967A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
US20120202836A1 (en) * 2009-10-23 2012-08-09 Tomasz Szczudlo Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
WO2013187967A1 (en) * 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN103768067A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104262262B (zh) * 2014-08-29 2016-06-08 西安交通大学 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
EP3624798A1 (en) * 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of mast cell diseases
CN108721217B (zh) * 2018-08-21 2020-09-08 武汉轻工大学 抗肿瘤药物组合物及药物制剂和应用
US20200297725A1 (en) * 2019-03-22 2020-09-24 Yale University Allosteric bcr-abl proteolysis targeting chimeric compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
KR20140048343A (ko) 2004-09-02 2014-04-23 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
WO2006102611A2 (en) * 2005-03-24 2006-09-28 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia

Also Published As

Publication number Publication date
US20130210771A1 (en) 2013-08-15
ES2422285T3 (es) 2013-09-10
SI2187967T1 (sl) 2013-07-31
RU2010109452A (ru) 2011-09-27
KR20100056525A (ko) 2010-05-27
JP2010536775A (ja) 2010-12-02
PL2187967T3 (pl) 2013-09-30
EP2187967A1 (en) 2010-05-26
CA2699988A1 (en) 2009-02-26
DK2187967T3 (da) 2013-07-22
US20100216828A1 (en) 2010-08-26
AU2008289255B2 (en) 2012-02-02
WO2009026075A1 (en) 2009-02-26
CN101820915A (zh) 2010-09-01
MX2010001813A (es) 2010-03-10
EP2187967B1 (en) 2013-04-24
US20120165355A1 (en) 2012-06-28
HRP20130642T1 (en) 2013-08-31
AU2008289255A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
CR10667A (es) Compositions and methods for diagnosing and treating cancer
BRPI0815330A2 (pt) métodos e composições para tratar cânceres
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI0820504A2 (pt) Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
PL3009148T3 (pl) Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0915205A2 (pt) compostos e composições úteis para o tratamento de malária
BRPI0819331A2 (pt) Métodos e composições para o tratamento do olho seco
BRPI0810525A2 (pt) Composições e métodos para a profilaxia e tratamento de dependência química
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
EP2125887A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
BRPI1012213A2 (pt) "solventes e composições para tratamento de formações contendo hidrocarboneto"
ATE526567T1 (de) Zusammensteller und zusammenstellungsverfahren
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]